{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:29:41Z","timestamp":1789709381116,"version":"4.0.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2407,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Augmentation therapy with intravenous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD). The recommended standard dose (SD; 60 mg\/kg\/wk) elevates AAT trough serum levels to around 50% of normal; however, outside of slowing emphysema progression, its effects in other clinical outcomes have not been rigorously proven.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the biological effects of normalizing AAT trough levels with double-dose (DD) therapy (120 mg\/kg\/wk) in subjects with AATD already receiving SD therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinically stable subjects were evaluated after 4 weeks of SD therapy, followed by 4 weeks of DD therapy, and 4 weeks after return to SD therapy. At the end of each phase, BAL fluid (BALF) and plasma samples were obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>DD therapy increased trough AAT levels to normal and, compared with SD therapy, reduced serine protease activity in BALF (elastase and cathepsin G), plasma elastase footprint (A\u03b1-Val360), and markers of elastin degradation (desmosine\/isodesmosine) in BALF. DD therapy also further downregulated BALF ILs and cytokines including Jak-STAT (Janus kinases\u2013signal transducer and activator of transcription proteins), TNF\u03b1 (tumor necrosis factor-\u03b1), and T-cell receptor signaling pathways, cytokines involved in macrophage migration, eosinophil recruitment, humoral and adaptive immunity, neutrophil activation, and cachexia. On restarting SD after DD treatment, a possible carryover effect was seen for several biological markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Subjects with AATD on SD augmentation therapy still exhibit inflammation, protease activity, and elastin degradation that can be further improved by normalizing AAT levels. Higher AAT dosing than currently recommended may lead to enhanced clinical benefits and should be explored further.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 01669421).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201901-0010oc","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T18:23:42Z","timestamp":1554834222000},"page":"318-326","source":"Crossref","is-referenced-by-count":74,"title":["The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial"],"prefix":"10.1093","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-9062","authenticated-orcid":false,"given":"Michael A.","family":"Campos","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1647-5505","authenticated-orcid":false,"given":"Patrick","family":"Geraghty","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Holt","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Mendes","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Newby","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuren","family":"Ma","sequence":"additional","affiliation":[{"name":"Mount Sinai Icahn School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landy V.","family":"Luna-Diaz","sequence":"additional","affiliation":[{"name":"Jackson Memorial Hospital, Miami, Florida; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"Turino","sequence":"additional","affiliation":[{"name":"Mount Sinai Icahn School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Stockley","sequence":"additional","affiliation":[{"name":"Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2026030321375311100_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","article-title":"A review of \u03b11-antitrypsin deficiency","volume":"185","author":"Stoller","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321375311100_bib2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ajpath.2014.04.015","article-title":"Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema","volume":"184","author":"Guyot","year":"2014","journal-title":"Am J Pathol"},{"key":"2026030321375311100_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.rmed.2011.02.002","article-title":"The discovery of \u03b11-antitrypsin and its role in health and disease","volume":"105","author":"Janciauskiene","year":"2011","journal-title":"Respir Med"},{"key":"2026030321375311100_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/cs0720373","article-title":"Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile","volume":"72","author":"Morrison","year":"1987","journal-title":"Clin Sci (Lond)"},{"key":"2026030321375311100_bib5","doi-asserted-by":"crossref","first-page":"291S","DOI":"10.1378\/chest.117.5_suppl_1.291S","article-title":"Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency","volume":"117","author":"Stockley","year":"2000","journal-title":"Chest"},{"key":"2026030321375311100_bib6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1034\/j.1399-3003.2000.15e12.x","article-title":"Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency","volume":"15","author":"Hill","year":"2000","journal-title":"Eur Respir J"},{"key":"2026030321375311100_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1378\/chest.111.2.394","article-title":"Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study Group","volume":"111","author":"McElvaney","year":"1997","journal-title":"Chest"},{"key":"2026030321375311100_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1164\/rccm.200703-489OC","article-title":"Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency","volume":"176","author":"Parr","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321375311100_bib9","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1073\/pnas.1309648110","article-title":"Anti-inflammatory and immunomodulatory properties of \u03b11-antitrypsin without inhibition of elastase","volume":"110","author":"Jonigk","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321375311100_bib10","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1513\/AnnalsATS.201509-634KV","article-title":"The role of neutrophils in alpha-1 antitrypsin deficiency","volume":"13","author":"McCarthy","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026030321375311100_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2119\/molmed.2011.00196","article-title":"Expanding the clinical indications for \u03b1(1)-antitrypsin therapy","volume":"18","author":"Lewis","year":"2012","journal-title":"Mol Med"},{"key":"2026030321375311100_bib12","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1164\/rccm.2109013","article-title":"The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency","volume":"165","author":"Stockley","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321375311100_bib13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1084\/jem.178.5.1629","article-title":"Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells","volume":"178","author":"Tilg","year":"1993","journal-title":"J Exp Med"},{"key":"2026030321375311100_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2121-5-11","article-title":"Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro","volume":"5","author":"Aldonyte","year":"2004","journal-title":"BMC Cell Biol"},{"key":"2026030321375311100_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fphar.2018.00341","article-title":"The multifaceted effects of alpha1-antitrypsin on neutrophil functions","volume":"9","author":"Janciauskiene","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026030321375311100_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-6-12","article-title":"Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release","volume":"6","author":"Nita","year":"2005","journal-title":"Respir Res"},{"key":"2026030321375311100_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1189\/jlb.0208145","article-title":"Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood","volume":"85","author":"Pott","year":"2009","journal-title":"J Leukoc Biol"},{"key":"2026030321375311100_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1165\/rcmb.2012-0515OC","article-title":"\u03b11-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-\u03b1","volume":"49","author":"Lockett","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026030321375311100_bib19","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI110360","article-title":"Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects","volume":"68","author":"Gadek","year":"1981","journal-title":"J Clin Invest"},{"key":"2026030321375311100_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"2026030321375311100_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","article-title":"Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)","volume":"5","author":"McElvaney","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026030321375311100_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12931-018-0844-6","article-title":"Health status decline in \u03b1-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?","volume":"19","author":"Stockley","year":"2018","journal-title":"Respir Res"},{"key":"2026030321375311100_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1378\/chest.100.3.703","article-title":"Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes","volume":"100","author":"Brantly","year":"1991","journal-title":"Chest"},{"key":"2026030321375311100_bib24","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.rmed.2009.04.008","article-title":"Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy","volume":"103","author":"Campos","year":"2009","journal-title":"Respir Med"},{"key":"2026030321375311100_bib25","first-page":"A6315","article-title":"The biological effects of double dose augmentation therapy for subjects with alpha-1 antitrypsin deficiency [abstract]","volume":"195","author":"Campos","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321375311100_bib26","first-page":"PA571","article-title":"Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT deficiency (AATD)","volume":"52","author":"Campos","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321375311100_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/15412555.2013.771163","article-title":"Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation","volume":"10","author":"Ma","year":"2013","journal-title":"COPD"},{"key":"2026030321375311100_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/thx.2010.154690","article-title":"The fibrinogen cleavage product A\u03b1-Val360, a specific marker of neutrophil elastase activity in vivo","volume":"66","author":"Carter","year":"2011","journal-title":"Thorax"},{"key":"2026030321375311100_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc"},{"key":"2026030321375311100_bib30","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.rmed.2007.04.010","article-title":"Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma","volume":"101","author":"Hollander","year":"2007","journal-title":"Respir Med"},{"key":"2026030321375311100_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1183\/09031936.00197411","article-title":"A\u03b1-Val360: a marker of neutrophil elastase and COPD disease activity","volume":"41","author":"Carter","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321375311100_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1378\/chest.14-0520","article-title":"The relationship of the fibrinogen cleavage biomarker A\u03b1-Val360 with disease severity and activity in \u03b11-antitrypsin deficiency","volume":"148","author":"Carter","year":"2015","journal-title":"Chest"},{"key":"2026030321375311100_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","article-title":"Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema","volume":"316","author":"Wewers","year":"1987","journal-title":"N Engl J Med"},{"key":"2026030321375311100_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/15412555.2013.800852","article-title":"Safety and pharmacokinetics of 120 mg\/kg versus 60 mg\/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)","volume":"10","author":"Campos","year":"2013","journal-title":"COPD"},{"key":"2026030321375311100_bib35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jama.1988.03410090091037","article-title":"Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency","volume":"260","author":"Hubbard","year":"1988","journal-title":"JAMA"},{"key":"2026030321375311100_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1378\/chest.112.3.607","article-title":"Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency","volume":"112","author":"Barker","year":"1997","journal-title":"Chest"},{"key":"2026030321375311100_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15412550902905961","article-title":"Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis","volume":"6","author":"Chapman","year":"2009","journal-title":"COPD"},{"key":"2026030321375311100_bib38","first-page":"CD007851","article-title":"Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease","volume":"9","author":"G\u00f8tzsche","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030321375311100_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1753465812438387","article-title":"Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy","volume":"6","author":"Barros-Tiz\u00f3n","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"2026030321375311100_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1753465810376407","article-title":"Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency","volume":"4","author":"K\u00f6hnlein","year":"2010","journal-title":"Ther Adv Respir Dis"},{"key":"2026030321375311100_bib41","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.00159408","article-title":"Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency","volume":"33","author":"Dirksen","year":"2009","journal-title":"Eur Respir J"},{"key":"2026030321375311100_bib42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/rccm.201405-0872OC","article-title":"\u03b11-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses","volume":"190","author":"Geraghty","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321375311100_bib43","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1513\/AnnalsATS.201509-574KV","article-title":"Biomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease","volume":"13","author":"Turino","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026030321375311100_bib44","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1073\/pnas.2235344100","article-title":"The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum","volume":"100","author":"Ma","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321375311100_bib45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1378\/chest.06-2251","article-title":"Measurements of desmosine and isodesmosine by mass spectrometry in COPD","volume":"131","author":"Ma","year":"2007","journal-title":"Chest"},{"key":"2026030321375311100_bib46","first-page":"34","article-title":"The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID\/RAPID extension trials","volume":"4","author":"Ma","year":"2016","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026030321375311100_bib47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/icb.2015.23","article-title":"Chemokines, their receptors and human disease: the good, the bad and the itchy","volume":"93","author":"Bryant","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"2026030321375311100_bib48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1034\/j.1399-3003.2000.15e28.x","article-title":"Airway neutrophils and interleukin-17","volume":"15","author":"Lind\u00e9n","year":"2000","journal-title":"Eur Respir J"},{"key":"2026030321375311100_bib49","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1084\/jem.192.11.1587","article-title":"Interferon gamma induction of pulmonary emphysema in the adult murine lung","volume":"192","author":"Wang","year":"2000","journal-title":"J Exp Med"},{"key":"2026030321375311100_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1465-9921-10-113","article-title":"Eosinophil and T cell markers predict functional decline in COPD patients","volume":"10","author":"D\u2019Armiento","year":"2009","journal-title":"Respir Res"},{"key":"2026030321375311100_bib51","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1172\/JCI41196","article-title":"\u03b1-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8","volume":"120","author":"Bergin","year":"2010","journal-title":"J Clin Invest"},{"key":"2026030321375311100_bib52","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.4049\/jimmunol.1400132","article-title":"Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals","volume":"193","author":"Hurley","year":"2014","journal-title":"J Immunol"},{"key":"2026030321375311100_bib53","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2353\/ajpath.2006.060058","article-title":"alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis","volume":"169","author":"Petrache","year":"2006","journal-title":"Am J Pathol"},{"key":"2026030321375311100_bib54","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1189\/jlb.0212071","article-title":"Alpha-1-antitrypsin inhibits nitric oxide production","volume":"92","author":"Chan","year":"2012","journal-title":"J Leukoc Biol"},{"key":"2026030321375311100_bib55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1096\/fj.00-0311com","article-title":"Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1","volume":"15","author":"Shapiro","year":"2001","journal-title":"FASEB J"},{"key":"2026030321375311100_bib56","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI113999","article-title":"Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice","volume":"83","author":"Carlson","year":"1989","journal-title":"J Clin Invest"},{"key":"2026030321375311100_bib57","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.4049\/jimmunol.0802864","article-title":"Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency","volume":"184","author":"Carroll","year":"2010","journal-title":"J Immunol"},{"key":"2026030321375311100_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"2026030321375311100_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1750-1172-8-149","article-title":"Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach","volume":"8","author":"Stockley","year":"2013","journal-title":"Orphanet J Rare Dis"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/3\/318\/67169451\/ajrccm_200_3_318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/3\/318\/67169451\/ajrccm_200_3_318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:38:07Z","timestamp":1772591887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/200\/3\/318\/8497154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201901-0010oc","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735517563.793576140","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]}}}